Search results for " VLDL"

showing 6 items of 26 documents

Dietary protein deficiency affects n-3 and n-6 polyunsaturated fatty acids hepatic storage and very low density lipoprotein transport in rats on diff…

1994

Fatty livers and the similarity between the skin lesions in kwashiorkor and those described in experimental essential fatty acid (EFA) deficiency have led to the hypothesis that protein and EFA deficiencies may both occur in chronic malnutrition. The relationship between serum very low density lipoprotein (VLDL) and hepatic lipid composition was studied after 28 d of protein depletion to determine the interactions between dietary protein levels and EFA availability. Rats were fed purified diets containing 20 or 2% casein and 5% fat as either soybean oil rich in EFA, or salmon oil rich in eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, or hydrogenated coconut, oil poor in EFA. Animal…

Malemedicine.medical_specialtyVery low-density lipoproteinfood.ingredientLow proteinDocosahexaenoic AcidsBiologyLipoproteins VLDLBiochemistrySoybean oilchemistry.chemical_compoundfoodEssential fatty acidInternal medicineCaseinFatty Acids Omega-6Protein DeficiencyFatty Acids Omega-3medicineAnimalsFood scienceRats WistarPhospholipidsTriglycerideschemistry.chemical_classificationFatty Acids EssentialOrganic Chemistryfood and beveragesFatty acidBiological TransportCell BiologyDietary FatsDietRatsEndocrinologychemistryEicosapentaenoic AcidLiverFatty Acids Unsaturatedlipids (amino acids peptides and proteins)Arachidonic acidDietary ProteinsPolyunsaturated fatty acidLipids
researchProduct

New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors

2011

Microsomal triglyceride transfer protein (MTP) is involved in the synthesis of very low density lipoprotein in the liver. Its deficiency results in abetalipoproteinemia. MTP inhibitors target the assembly and secretion of apolipoprotein B-containing lipoproteins. These agents may potentially play a role, alone or in combination, in the treatment of hypercholesterolemia or hypertriglyceridemia. Clinical applications of MTP inhibitors initially focused primarily on high-dose monotherapy in order to produce substantial reductions in LDL-cholesterol levels but these proved to induce significant hepatic steatosis and transaminase elevations. However, likely orphan indications for MTP inhibitors,…

Very low-density lipoproteinApolipoprotein BHypercholesterolemiaFamilial hypercholesterolemiaLipoproteins VLDLPharmacologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundMicrosomesDrug DiscoveryClinical endpointHumansMedicineApolipoproteins BHypertriglyceridemiaPharmacologybiologybusiness.industryCholesterolAbetalipoproteinemiamedicine.diseaseAbetalipoproteinemiaBiochemistrychemistryMTP-inhibitors lipids lipoproteins atherosclerosis cardiovascular prevention.biology.proteinlipids (amino acids peptides and proteins)SteatosisCarrier ProteinsbusinessCurrent Pharmaceutical Design
researchProduct

Interaction of pHPMA–pLMA Copolymers with Human Blood Serum and Its Components

2013

Immediately after administration, polymer therapeutics are exposed to complex biological media like blood which may influence and alter their physicochemical properties due to interactions with proteins or serum components. Among such interactions those leading to larger sized aggregates can be sensitively detected by dynamic light scattering (DLS) as a pre in vivo screening method. Random copolymers from N-(2-hydroxypropyl)methacrylamide and lauryl methacrylate p(HPMA-co-LMA) and copolymers loaded with the model drug domperidone were characterized by DLS in isotonic salt solution and in blood serum. The bare amphiphilic copolymer micelles (Rh=30 nm in isotonic salt solution) formed large a…

chemistry.chemical_classificationChromatographyPolymersPharmaceutical SciencePolymerLipoproteins VLDLMicelleDomperidoneLipoproteins LDLchemistry.chemical_compoundBlood serumchemistryDynamic light scatteringIn vivoDrug DiscoveryBiophysicsmedicineCopolymerHumansMolecular MedicineMethacrylamideMicellesmedicine.drugMolecular Pharmaceutics
researchProduct

Moderate consumption of beer reduces liver triglycerides and aortic cholesterol deposit in LDLr-/- apoB100/100 mice.

2006

This study was designed to address the effects of a moderate consumption of beer on serum and liver lipid parameters and on the development of aortic lesions in a mouse model associated with a human atherogenic lipoprotein profile. LDLr(-/-) apoB(100/100) mice received each day during 12 weeks either water, mild beer (0.570g of ethanol/kg of body weight) or ethanol-free beer in a single pure dose. Serum and liver lipid parameters were analyzed and atherosclerotic lesions were estimated in heart and aorta through their total cholesterol content. mRNA levels of enzymes and receptors involved in lipoprotein uptake, in fatty acid esterification and oxidation, and in reverse cholesterol transpor…

medicine.medical_specialtyApolipoprotein BAlcohol DrinkingCholesterol VLDLAortic DiseasesPalmitatesDown-RegulationAorta ThoracicMitochondria LiverPolymerase Chain ReactionPhosphatidylcholine-Sterol O-Acyltransferasechemistry.chemical_compoundMiceInternal medicinemedicineAnimalsRNA MessengerScavenger receptorChromatography High Pressure LiquidTriglyceridesApolipoproteins BbiologyTriglycerideCholesterolReverse cholesterol transportCholesterol HDLfood and beveragesBeerLipoprotein(a)Cholesterol LDLScavenger Receptors Class BAtherosclerosisMice Inbred C57BLEndocrinologychemistryLiverReceptors LDLLDL receptorbehavior and behavior mechanismsbiology.proteinlipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineOxidation-ReductionLipoproteinSterol Regulatory Element Binding Protein 2Atherosclerosis
researchProduct

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertas…

2021

OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-…

medicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismLipoproteinsAdipose tissue030209 endocrinology & metabolismLipoproteins VLDL03 medical and health sciencesMice0302 clinical medicineInternal medicineInternal MedicinemedicineAnimalsHumans030212 general & internal medicineSubtilisinsAdvanced and Specialized NursingbiologyCatabolismLiraglutidebusiness.industryPCSK9Liraglutidemedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2biology.proteinKexinProprotein Convertase 9businessRetinol-Binding Proteins PlasmaDyslipidemiamedicine.drugLipoprotein
researchProduct

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms

2001

To induce atherogenesis in mice, a high fat (HF) diet is supplemented with cholic acid (CA), which increases apoB-containing particles and lower apoA-I-containing particles. HF diet without CA increases levels of both HDL and LDL, suggesting that CA may be responsible for the elevation of LDL and lowering of HDL. The mechanism of dietary CA-induced lowering of apoA-I-containing particles has recently been reported. In this study, we examined the mechanism of CA- and HF-induced elevation of apoB-containing lipoproteins in mice. Mice were fed the following four diets: control chow (C), high fat high cholesterol, (HF), control and 0.5% cholate (CA), and HF + CA. Dietary CA increased the plasma…

medicine.medical_specialtyVery low-density lipoproteinSettore MED/09 - Medicina InternaMouseApolipoprotein Bmedicine.medical_treatmentDown-RegulationCholic AcidLipoproteins VLDLBiochemistryDietary cholateMicechemistry.chemical_compoundApolipoproteins ERibonucleasesDownregulation and upregulationInternal medicinemedicineAnimalsVitamin ERNA MessengerRNA Processing Post-TranscriptionalReceptorApolipoproteins BbiologyChemistryVitamin ECholic acidnutritional and metabolic diseasesCell BiologyBlotting NorthernDietLipoproteins LDLMice Inbred C57BLCholesterolEndocrinologyLiverReceptors LDLLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Gene expressionHepatic lipaseApolipoprotein BCholatesDietary fatThe International Journal of Biochemistry & Cell Biology
researchProduct